|
|---|
click on the picture above
to interact |
 |
C18H24N4O |
Granisetron isused to treat nausea and vomiting following chemotherapy. Its main affect is to reduce the activity of the vagus nerve, which is a nerve that activates the vomiting center in the medulla oblongata. It does not have much effect on vomiting due to motion sickness.
Granisetron was developed by chemists working at the British drug company Beecham. It is now produced by Roche Laboratories under the trade name KytrilŪ. The drug was approved in the United Kingdom in 1991 and in United States in 1994 by the FDA.
Granisetron is often intravenously about 30 minutes before beginning chemotherapy.
Formal Chemical Name (IUPAC)
1-methyl-N-((1R,3S,5S)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-1H-indazole-3-carboxamide
References
http://en.wikipedia.org/wiki/Kytril
Update by Karl Harrison
(Molecule of the Month for
October 2006
)